Published in Int J Cancer on May 01, 1994
Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest (2003) 1.42
Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest (2006) 1.40
The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects. J Exp Med (2009) 1.05
In vivo evaluation of the early events associated with liver metastasis of circulating cancer cells. Br J Cancer (2001) 0.96
Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor. J Exp Med (1998) 0.92
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet (2001) 5.75
Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol (1999) 3.36
Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ (2007) 3.22
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (1999) 3.19
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg (2001) 2.94
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch (2001) 2.73
Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Italian Study Group. Br J Surg (1994) 2.51
Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer (2005) 2.32
Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer (1995) 2.28
Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med (1993) 2.24
A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother (2001) 2.18
Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med (1991) 2.11
Diagnosis, objective assessment of severity, and management of acute pancreatitis. Santorini consensus conference. Int J Pancreatol (1999) 2.03
Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer (1999) 1.99
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol (2006) 1.95
Guidelines for the management of acute pancreatitis. J Gastroenterol Hepatol (2002) 1.92
A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet (1993) 1.91
Enucleation of pancreatic neoplasms. Br J Surg (2007) 1.88
Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev (2003) 1.74
Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer (2009) 1.69
Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene (2006) 1.69
Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg (2010) 1.68
Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene (2001) 1.68
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest (1996) 1.64
Tumour-associated transplantation antigens of chemically induced sarcomata cross reacting with allogeneic histocompatibility antigens. Nature (1975) 1.60
Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer. Dig Dis Sci (1999) 1.59
Distribution and anomalies of coronary arteries in tetralogy of fallot. Circulation (1980) 1.58
High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke (1998) 1.57
Isolation measures for prevention of infection with respiratory pathogens in cystic fibrosis: a systematic review. J Hosp Infect (2006) 1.57
Clinicopathological features and treatment of intraductal papillary mucinous tumour of the pancreas. Br J Surg (2001) 1.53
Five-year follow-up of 10 patients treated with globus pallidus internus deep brain stimulation for segmental or multisegmental dystonia. Stereotact Funct Neurosurg (2012) 1.48
Infected pancreatic necrosis and peripancreatic fluid collections: serendipitous response to antibiotics and medical therapy in three patients. Pancreas (1996) 1.47
The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A (1999) 1.47
Prevalence and risk factors of extrapancreatic malignancies in a large cohort of patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Oncol (2013) 1.47
Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol (2001) 1.47
Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer (1994) 1.44
Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. J Exp Med (1993) 1.43
Alcohol intake, cigarette smoking, and body mass index in patients with alcohol-associated pancreatitis. J Clin Gastroenterol (2000) 1.42
Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol (2003) 1.42
Changes in pancreatic resection for chronic pancreatitis over 28 years in a single institution. Br J Surg (2000) 1.40
Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res (1992) 1.39
[ICU patients and days of intensive care: A mathematical model optimizing the consequences of ICU unit function, intensive care and continual monitoring on incurred supplementary costs]. Ann Fr Anesth Reanim (2013) 1.39
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J Exp Med (1996) 1.38
Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer (2001) 1.36
HOXB7 constitutively activates basic fibroblast growth factor in melanomas. Mol Cell Biol (1996) 1.35
Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma. Int J Cancer (1985) 1.29
Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol (1999) 1.24
Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol (1994) 1.24
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med (1995) 1.24
Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol (2008) 1.23
Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med (1999) 1.22
Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer. Br J Surg (1998) 1.22
Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol (2013) 1.20
Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol (1995) 1.18
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest (1998) 1.17
Long-term follow-up of patients with chronic pancreatitis in Italy. Scand J Gastroenterol (1998) 1.15
Primary but not metastatic human melanomas expressing DR antigens stimulate autologous lymphocytes. Int J Cancer (1984) 1.15
Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res (2001) 1.12
CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol (1995) 1.11
Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. Br J Surg (2012) 1.10
Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. J Immunol (1989) 1.10
Leber's Hereditary Optic Neuropathy (LHON) with 14484/ND6 mutation in a North African patient. J Neurol Sci (1998) 1.10
Increased killer cell activity in insulin dependent (type 1) diabetes mellitus. Diabetologia (1981) 1.09
Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res (1998) 1.09
Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol (1998) 1.08
Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol (1996) 1.07
Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene (2011) 1.06
Prospective multicentre survey on acute pancreatitis in Italy (ProInf-AISP): results on 1005 patients. Dig Liver Dis (2004) 1.06
Alcohol, smoking and papillomavirus infection as risk factors for esophageal squamous-cell papilloma and esophageal squamous-cell carcinoma in Italy. Int J Cancer (2000) 1.06
Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb. Cancer Res (1991) 1.05
IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene (2010) 1.05
Effect of different sera on growth and "spontaneous" neoplastic transformation of mouse fibroblasts in vitro. J Natl Cancer Inst (1974) 1.05
Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. Eur J Cancer (1990) 1.05
Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res (1996) 1.05
"Paraduodenal" pancreatitis: results of surgery on 58 consecutives patients from a single institution. World J Surg (2009) 1.05
Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. Melanoma Res (1992) 1.04
Conservative treatment of external pancreatic fistulas with parenteral nutrition alone or in combination with continuous intravenous infusion of somatostatin, glucagon or calcitonin. Surg Gynecol Obstet (1986) 1.04
Monoclonal antibodies defined abnormalities of T-lymphocytes in type I (insulin-dependent) diabetes. Diabetes (1983) 1.04
Heterogeneity in human melanoma cell adhesion to cytokine activated endothelial cells correlates with VLA-4 expression. Cancer Res (1991) 1.03
Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells. Int J Cancer (1997) 1.02
Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev (2006) 1.02
Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. J Immunol (1996) 1.02
Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis (2008) 1.02
Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use. Cancer Immunol Immunother (1994) 1.01
Cigarette smoking: an independent risk factor in alcoholic pancreatitis. Pancreas (1996) 0.99
Alien histocompatibility determinants on the cell surface of sarcomas induced by methylcholanthrene. I. In vivo studies. Int J Cancer (1975) 0.99
A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res (1999) 0.99